CSIMarket Company Name, Ticker, Industry, else..
 
Vor Biopharma Inc   (NASDAQ: VOR)
 

Vor Biopharma Inc's Suppliers Performance

VOR's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
VOR Costs vs Sales of Suppliers Growth

• More on VOR Suppliers






Vor Biopharma Inc's Comment on Supply Chain


The company sources raw materials, manufacturing devices, active pharmaceutical ingredients, and finished products for research and clinical manufacturing from third-party suppliers. It does not currently have long-term agreements or contractual relationships for manufacturing materials beyond Phase 3 clinical trials or commercial supplies. The company plans to establish agreements with third-party contract manufacturers and backup manufacturers for future production and is evaluating the feasibility of developing its own manufacturing capabilities. All manufacturing processes and facilities must comply with FDA and other regulatory requirements. One specific supplier is RemeGen, with whom the company has a license agreement for telitacicept. This agreement includes a non-exclusive license to manufacture the licensed products worldwide for use in the licensed territory, while RemeGen retains manufacturing rights in Greater China.

Vor Biopharma Inc's Comment on Supply Chain


The company sources raw materials, manufacturing devices, active pharmaceutical ingredients, and finished products for research and clinical manufacturing from third-party suppliers. It does not currently have long-term agreements or contractual relationships for manufacturing materials beyond Phase 3 clinical trials or commercial supplies. The company plans to establish agreements with third-party contract manufacturers and backup manufacturers for future production and is evaluating the feasibility of developing its own manufacturing capabilities. All manufacturing processes and facilities must comply with FDA and other regulatory requirements. One specific supplier is RemeGen, with whom the company has a license agreement for telitacicept. This agreement includes a non-exclusive license to manufacture the licensed products worldwide for use in the licensed territory, while RemeGen retains manufacturing rights in Greater China.







VOR's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Vor Biopharma Inc 1,162.12 0.00 627.78 76
SUBTOTAL 0.00 0.00 0.00 -


Sources: Vor Biopharma Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Vor Biopharma Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.